← Eichor
Study identifier: NCT06660056 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas

Condition: High-grade Gliomas  ·  Sponsor: GONGCHU Biotechnology Co., Ltd

PhasePhase 1
Planned participants35
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

A Phase I Study Evaluating the Safety, Tolerability, Biodistribution and Shedding of the Virus, Pharmacodynamics, Immunogenicity, and Antitumor Activity of GC001 Oncolytic Vaccinia Virus Injection in Patient With Recurrent or Progressive Gliomas .

This description comes directly from the study's public registry record.

Talk to the study team

Mo guoyu  ·  13710803863  ·  morlon_pla@126.com

li wenbin, Professor

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Tiantan Hospital,Capital Medical UniversityBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06660056